Pacira BioSciences (STU:82P) Cyclically Adjusted Book per Share: €13.45 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:82P Pacira BioSciences Inc STU:82P
72 GF Score
Price €21.40
GF Value €25.24
! 7 Warning Signs
View Full Analysis

What is Pacira BioSciences Cyclically Adjusted Book per Share?

Pacira BioSciences STU:82P -0.93% 72 Cyclically Adjusted Book per Share is €13.45 as of Jun. 2026. GuruFocus rates STU:82P with a GF Score™ of 72/100 and a GF Value™ of €25.24. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Pacira BioSciences's adjusted book value per share for the three months ended in Jun. 2026 was €14.759. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €13.45 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Pacira BioSciences's average Cyclically Adjusted Book Growth Rate was 9.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 14.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 20.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Pacira BioSciences was 28.90% per year. The lowest was 14.80% per year. And the median was 22.60% per year.

As of today (2026-09-18), Pacira BioSciences's current stock price is €21.40. Pacira BioSciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €13.45. Pacira BioSciences's Cyclically Adjusted PB Ratio of today is 1.59.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pacira BioSciences was 13.51. The lowest was 0.95. And the median was 4.59.


Pacira BioSciences  (STU:82P) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pacira BioSciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=21.40/13.45
=1.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pacira BioSciences was 13.51. The lowest was 0.95. And the median was 4.59.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Pacira BioSciences Cyclically Adjusted Book per Share Related Terms


Pacira BioSciences Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Cyclically Adjusted Book per Share Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.94 8.77 10.64 12.05 13.06

Pacira BioSciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.29 12.56 12.71 13.12 13.45

STU:82P vs AMPH, COLL, IRWD: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacira BioSciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pacira BioSciences's Cyclically Adjusted PB Ratio falls into.


STU:82P
72GF Score
Pacira BioSciences Inc STU:82P
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacira BioSciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14.759/333.9520*333.9520
=14.759

Current CPI (Jun. 2026) = 333.9520.

Pacira BioSciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 5.112 241.428 7.071
201612 5.539 241.432 7.662
201703 6.322 243.801 8.660
201706 5.677 244.955 7.740
201709 5.522 246.819 7.471
201712 5.723 246.524 7.753
201803 5.562 249.554 7.443
201806 6.076 251.989 8.052
201809 6.317 252.439 8.357
201812 6.817 251.233 9.062
201903 7.065 254.202 9.281
201906 7.211 256.143 9.401
201909 7.614 256.759 9.903
201912 7.545 256.974 9.805
202003 8.094 258.115 10.472
202006 8.111 257.797 10.507
202009 11.512 260.280 14.770
202012 11.606 260.474 14.880
202103 12.597 264.877 15.882
202106 13.040 271.696 16.028
202109 13.926 274.310 16.954
202112 14.358 278.802 17.198
202203 14.152 287.504 16.438
202206 15.802 296.311 17.809
202209 17.140 296.808 19.285
202212 15.811 296.797 17.790
202303 15.378 301.836 17.014
202306 15.958 305.109 17.467
202309 16.917 307.789 18.355
202312 16.947 306.746 18.450
202403 17.758 312.332 18.987
202406 17.790 314.175 18.910
202409 14.554 315.301 15.415
202412 16.255 315.605 17.200
202503 15.972 319.799 16.679
202506 14.378 322.561 14.886
202509 14.405 324.800 14.811
202512 14.353 324.054 14.791
202603 14.437 330.213 14.600
202606 14.759 333.952 14.759

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €13.45 mean?
Pacira BioSciences (STU:82P) has a Cyclically Adjusted Book per Share of €13.45 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Cyclically Adjusted Book per Share too high?
Pacira BioSciences' current Cyclically Adjusted Book per Share is €13.45. Overall, Pacira BioSciences has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Cyclically Adjusted Book per Share compare to AMPH and COLL?
Pacira BioSciences' Cyclically Adjusted Book per Share of €13.45 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Cyclically Adjusted Book per Share is €13.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (STU:82P) has a current Cyclically Adjusted Book per Share of €13.45. The stock's GF Value™ is €25.24, compared to a current price of €21.40 — trading 15.2% below its estimated fair value. The current Cyclically Adjusted Book per Share is €13.45. Pacira BioSciences' overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Pacira BioSciences (STU:82P), the current Cyclically Adjusted Book per Share is €13.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (STU:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €21.40 is trading 15.2% below its estimated GF Value™ of €25.24.

Key valuation signals for STU:82P:

  • Cyclically Adjusted Book per Share: €13.45
  • GF Value™: €25.24 vs. price of €21.40 (15.2% below fair value)
  • GF Score™: 72/100 with 7 warning signs

No single metric tells the full story. See the STU:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacira BioSciences Business Description

Other Exchanges PCRX:USA
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
72GF Score

Get the complete analysis for STU:82P

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.40
Price
€25.24
GF Value